[Retracted] Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma

Table 5

Comparison of efficacy according to different starting states in included patients.

Subgroups	Treatment cycle	Original research drug group			Generic drug group
		>=VGPR	Sample	Total efficacy rate (%)	>=VGPR	Sample	Total efficacy rate (%)
Initial treatment MM	1	17 (0.13)	127	13.39	21 (0.21)	102	20.59	0.145
	2	38 (0.30)	127	29.92	30 (0.29)	102	29.41	0.933
	3	72 (0.57)	126	57.14	62 (0.63)	98	63.27	0.354
	4	82 (0.68)	121	67.77	69 (0.76)	91	75.82	0.200
	5	80 (0.67)	119	67.23	63 (0.78)	81	77.78	0.105
	6	79 (0.71)	111	71.17	62 (0.82)	76	81.58	0.105
Recurrence/progression MM	1	3 (0.14)	22	13.64	1 (0.06)	18	5.56	0.397
	2	6 (0.27)	22	27.27	1 (0.06)	18	5.56	0.072
	3	8 (0.38)	21	38.10	3 (0.19)	16	18.75	0.202
	4	10 (0.56)	18	55.56	6 (0.43)	14	42.86	0.476
	5	11 (0.61)	18	61.11	6 (0.43)	14	42.86	0.305
	6	11 (0.85)	13	84.62	9 (0.64)	14	64.29	0.228